// App-Quantinova.ai

: Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Iman Aboudalle

Principal Investigators

  • Hagop M. Kantarjian

  • Nicholas J Short

  • Farhad Ravandi

  • Koji Sasaki

  • Guillermo Garcia-Manero

  • Guillermo Montalban-Bravo

  • Jorge E. Cortes

  • Christopher B. Benton

  • Ghayas C. Issa

  • Maria Khouri

  • Patrice Nasnas

  • Susan M. O'Brien

  • Elias J. Jabbour

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Chao Family Comprehensive Cancer Center, University of California, Orange, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Cytokine release syndrome

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Blinatumomab

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved